BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8342582)

  • 1. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
    Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS; Quarles LD
    Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
    Teruel JL; Tenorio MT; Rodríguez JR; Marc n R; Orofino L; Rivera M; Ortuño J
    Am J Nephrol; 1999; 19(3):428-32. PubMed ID: 10393383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
    Takahashi S; Okada K; Kinosita Y; Yanai M; Kuno T; Nagura Y
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
    Kawabe M; Shimizu M; Takeuchi M; Matsunobu S; Hayama N; Iino Y; Hara K; Terashi A
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):807-11. PubMed ID: 1479720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure.
    Tsukamoto Y; Moriya R; Nagaba Y; Morishita T; Izumida I; Okubo M
    Am J Kidney Dis; 1995 Jun; 25(6):879-86. PubMed ID: 7771484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.